Surface Modification of Lipid-Based Nanocarriers: A Potential Approach to Enhance Targeted Drug Delivery
Overview
Affiliations
Nanocarriers have the utmost significance for advancements in drug delivery and nanomedicine technology. They are classified as polymer-based nanocarriers, lipid-based nanocarriers, viral nanoparticles, or inorganic nanoparticles, depending on their constituent parts. Lipid-based nanocarrier systems have gained tremendous attention over the years because of their noteworthy properties like high drug-loading capacity, lower toxicity, better bioavailability and biocompatibility, stability in the gastrointestinal tract, controlled release, simpler scale-up, and validation process. Nanocarriers still have some disadvantages like poor drug penetration, limited drug encapsulation, and poor targeting. These disadvantages can be overcome by their surface modification. Surface-modified nanocarriers result in controlled release, enhanced penetration efficiency, and targeted medication delivery. In this review, the authors summarize the numerous lipid-based nanocarriers and their functionalization through various surface modifiers such as polymers, ligands, surfactants, and fatty acids. Recent examples of newly developing surface-modified lipid-based nanocarrier systems from the available literature, along with their applications, have been compiled in this work.
Prajapati S, Jain A, Bajpai M RSC Adv. 2025; 15(10):7799-7825.
PMID: 40070389 PMC: 11895809. DOI: 10.1039/d5ra00387c.
Theivendren P, Kunjiappan S, Pavadai P, Ravi K, Murugavel A, Dayalan A ACS Meas Sci Au. 2025; 5(1):31-55.
PMID: 39991031 PMC: 11843507. DOI: 10.1021/acsmeasuresciau.4c00062.
Navigating liver cancer: Precision targeting for enhanced treatment outcomes.
Jain A, Mishra A, Hurkat P, Shilpi S, Mody N, Jain S Drug Deliv Transl Res. 2025; .
PMID: 39847205 DOI: 10.1007/s13346-024-01780-x.
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.
Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.
PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.
Desai O, Kumar S, Koster M, Ullah S, Sarker S, Hagemann V Drug Deliv Transl Res. 2025; .
PMID: 39804440 DOI: 10.1007/s13346-024-01774-9.